We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

94 hedge funds and large institutions have $482M invested in Applied Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,040% more call options, than puts

Call options by funds: $4.97M | Put options by funds: $436K

41% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 22

25% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 24

6% more funds holding

Funds holding: 8994 (+5)

1.64% more ownership

Funds ownership: 88.74%90.38% (+1.6%)

25% less capital invested

Capital invested by funds: $639M → $482M (-$157M)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
94
Holders Change
+5
Holders Change %
+5.62%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
30
Increased
31
Reduced
22
Closed
24
Calls
$4.97M
Puts
$436K
Net Calls
+$4.53M
Net Calls Change
-$39.5M
Name Holding Trade Value Shares
Change
Change in
Stake
SFM
26
Sphera Funds Management
Israel
$3.15M +$261K +55,239 +9%
LGM
27
Logos Global Management
California
$2.66M -$3.55M -750,000 -56%
SSA
28
Schonfeld Strategic Advisors
New York
$2.49M -$6.17M -1,302,913 -71%
Walleye Capital
29
Walleye Capital
New York
$1.88M +$445K +94,049 +31%
ACM
30
ADAR1 Capital Management
Texas
$1.5M -$643K -135,861 -30%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.33M +$1.34M +283,793 New
Charles Schwab
32
Charles Schwab
California
$1.29M +$1.2M +252,773 +1,032%
N
33
Nuveen
North Carolina
$1.27M +$1.29M +271,613 New
Northern Trust
34
Northern Trust
Illinois
$1.09M +$603K +127,331 +120%
Bank of America
35
Bank of America
North Carolina
$1.07M +$920K +194,317 +547%
Macquarie Group
36
Macquarie Group
Australia
$1.07M +$1.05M +222,417 +3,302%
CC
37
Checkpoint Capital
California
$1.06M +$35.3K +7,470 +3%
HWAM
38
Hennion & Walsh Asset Management
New Jersey
$920K +$932K +197,042 New
UBS Group
39
UBS Group
Switzerland
$804K +$91.3K +19,303 +13%
Goldman Sachs
40
Goldman Sachs
New York
$712K -$2.66M -562,759 -79%
Rockefeller Capital Management
41
Rockefeller Capital Management
New York
$701K
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
$700K -$1.46M -309,146 -67%
BCM
43
Bridgeway Capital Management
Texas
$695K -$118K -25,000 -14%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$625K +$631K +133,351 +24,513%
SEI Investments
45
SEI Investments
Pennsylvania
$535K +$542K +114,619 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$527K -$1.76M -371,966 -77%
Millennium Management
47
Millennium Management
New York
$518K -$3.86M -815,517 -88%
Jane Street
48
Jane Street
New York
$513K -$638K -134,786 -55%
AA
49
ALPS Advisors
Colorado
$416K +$422K +89,131 New
Citadel Advisors
50
Citadel Advisors
Florida
$357K +$347K +73,344 +2,359%

APLT Hedge Fund Activity: Q2 2024 in Review

94 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q2 2024, worth a combined $482M — down 25% from $639M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new APLT positions and 24 closed out — a net gain of 6 holders — while 31 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $26.4M. The largest seller was Laurion Capital Management, cutting an estimated $6.77M.

  • 94 institutional investors held Applied Therapeutics (APLT) as of Q2 2024, up from 89 in Q1 2024.
  • Funds reported $482M of Applied Therapeutics stock for Q2 2024, down 25% quarter-over-quarter.
  • 30 funds opened new Applied Therapeutics positions in Q2 2024 and 24 closed out, a net change of +6 holders.
  • The largest Applied Therapeutics buyer in Q2 2024 was BlackRock, an estimated $26.4M added.
  • The largest Applied Therapeutics seller in Q2 2024 was Laurion Capital Management, an estimated $6.77M sold.

Based on aggregated 13F filings for Q2 2024.